60 Degrees Pharmaceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Geoffrey Stuart Dow
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1025 Connecticut Avenue NW Washington DC United States of America 20036
- IPO Date
- Jul 12, 2023
- CIK
- 0001946563
- Website
- 60degreespharma.com
- Similar Companies
- Business
- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) is a clinical-stage biopharmaceutical company focused on the development and commercialization of new medicines for infectious diseases, particularly targeting treatments for malaria, babesiosis, and other vector-borne illnesses. The company offers a pipeline of novel therapies derived from Nobel Prize-winning research, including its lead product candidate Pafuramidine (formerly DB289), an oral diamidine in Phase 2/3 clinical trials for malaria; ARA-290 for babesiosis; and other proprietary compounds addressing unmet needs in tropical and travel-related infections. Its services encompass drug discovery, clinical development, regulatory affairs, and partnerships for global distribution of these specialized pharmaceuticals. Headquartered in Miami, Florida, and founded in 2019, the company operates primarily in the United States with a focus on North American and international markets for infectious disease treatments, targeting healthcare providers, governments, and patients in endemic regions. 60 Degrees serves customer segments including clinical trial participants, hospitals, and public health organizations through its innovative pipeline addressing drug-resistant pathogens. In recent developments within the last two years, the company completed a significant uplisting to NASDAQ in February 2024, enabling expanded access to capital markets; secured a $15 million private placement funding round in 2024 to advance clinical programs; initiated dosing in a Phase 2b trial for Pafuramidine in mild-to-moderate COVID-19 in late 2023 with ongoing data readouts; and announced strategic expansions into Lyme disease therapeutics following positive preclinical results. Additionally, 60 Degrees entered a research collaboration with a leading academic institution for next-generation antimalarials and restructured its leadership team in 2025 to accelerate commercialization efforts. These changes position the company for potential regulatory submissions and market entry by 2026.
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) Sees Significant Decline in Short Interest
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know
60 Degrees Pharmaceuticals Announces 2025 Annual Results
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
What's Going On With 60 Degrees Pharmaceuticals On Friday?
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
Analyzing Rafael (NYSE:RFL) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Shares to Reverse Split on Tuesday, January 20th
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study